Biogen Inc on Thursday laid out more data on its experimental Alzheimer’s drug that raised no major safety alarms but also offered little compelling evidence the drug, once declared a failure, actually works.
Biogen Inc on Thursday laid out more data on its experimental Alzheimer’s drug that raised no major safety alarms but also offered little compelling evidence the drug, once declared a failure, actually works.